Elucidating feed‑forward apoptosis signatures in breast cancer datasets: Higher FOS expression associated with a better outcome

Fisler,Diana  A.; Sikaria,Dhiraj; Yavorski,John  M.; Tu,Yaping  N.; Blanck,George

doi:10.3892/ol.2018.8957

Elucidating feed‑forward apoptosis signatures in breast cancer datasets: Higher FOS expression associated with a better outcome

Authors:
- Diana A. Fisler
- Dhiraj Sikaria
- John M. Yavorski
- Yaping N. Tu
- George Blanck
View Affiliations

Affiliations: Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA
Published online on: June 12, 2018 https://doi.org/10.3892/ol.2018.8957
Pages: 2757-2763

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Overstimulation of pro‑proliferative pathways and high level expression of pro‑proliferative transcription factors (TFs) can lead to apoptosis. This is likely due to TF binding sites for pro‑proliferative TFs common to pro‑proliferative and pro‑apoptosis‑effector genes. Certain clinical datasets have indicated that molecular markers associated with higher proliferation rates lead to improved outcomes for patients with cancer. These observations have been extensively assessed on a general basis, however there has been little work dissecting feed‑forward apoptosis signaling pathways that may represent specific distinctions between a pro‑proliferative mechanism and a pro‑apoptotic mechanism in samples from patients with cancer. Using The Cancer Genome Atlas datasets and bioinformatic approaches, the present study reports that higher FOS expression levels, along with higher FOS target apoptosis‑effector gene expression, is associated with an increased survival, while higher POU2F1 expression is associated with a reduced survival (average difference of 25.9 months survival). In summary, in the datasets examined FOS represents an apoptosis‑driver and high POU2F1 represents a driver mechanism for cancer development.

View Figures

View References

1	Truman JP, Choqueux C, Charron D and Mooney N: HLA class II molecule signal transduction leads to either apoptosis or activation via two different pathways. Cell Immunol. 172:149–157. 1996. View Article : Google Scholar : PubMed/NCBI
2	Ford SA and Blanck G: Signal persistence and amplification in cancer development and possible, related opportunities for novel therapies. Biochim Biophys Acta. 1855:18–23. 2015.PubMed/NCBI
3	Macián F, Im SH, García-Cózar FJ and Rao A: T-cell anergy. Curr Opin Immunol. 16:209–216. 2004. View Article : Google Scholar : PubMed/NCBI
4	Szekeres K, Koul R, Mauro J, Lloyd M, Johnson J and Blanck G: An Oct-1-based, feed-forward mechanism of apoptosis inhibited by co-culture with Raji B-cells: Towards a model of the cancer cell/B-cell microenvironment. Exp Mol Pathol. 97:585–589. 2014. View Article : Google Scholar : PubMed/NCBI
5	Field SJ, Tsai FY, Kuo F, Zubiaga AM, Kaelin WG Jr, Livingston DM, Orkin SH and Greenberg ME: E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell. 85:549–561. 1996. View Article : Google Scholar : PubMed/NCBI
6	Wu X and Levine AJ: p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad Sci USA. 91:3602–3606. 1994. View Article : Google Scholar : PubMed/NCBI
7	Yamasaki L, Jacks T, Bronson R, Goillot E, Harlow E and Dyson NJ: Tumor induction and tissue atrophy in mice lacking E2F-1. Cell. 85:537–548. 1996. View Article : Google Scholar : PubMed/NCBI
8	Oswald F, Dobner T and Lipp M: The E2F transcription factor activates a replication-dependent human H2A gene in early S phase of the cell cycle. Mol Cell Biol. 16:1889–1895. 1996. View Article : Google Scholar : PubMed/NCBI
9	Banerjee D, Ercikan-Abali E, Waltham M, Schnieders B, Hochhauser D, Li WW, Fan J, Gorlick R, Goker E and Bertino JR: Molecular mechanisms of resistance to antifolates, a review. Acta Biochim Pol. 42:457–464. 1995.PubMed/NCBI
10	Berry DE, Lu Y, Schmidt B, Fallon PG, O'Connell C, Hu SX, Xu HJ and Blanck G: Retinoblastoma protein inhibits IFN-gamma induced apoptosis. Oncogene. 12:1809–1819. 1996.PubMed/NCBI
11	McKay BC, Becerril C, Spronck JC and Ljungman M: Ultraviolet light-induced apoptosis is associated with S-phase in primary human fibroblasts. DNA Repair (Amst). 1:811–820. 2002. View Article : Google Scholar : PubMed/NCBI
12	Mauro JA and Blanck G: Functionally distinct gene classes as bigger or smaller transcription factor traps: A possible stochastic component to sequential gene expression programs in cancer. Gene. 536:398–406. 2014. View Article : Google Scholar : PubMed/NCBI
13	Garcia M, Mauro JA, Ramsamooj M and Blanck G: Tumor suppressor genes are larger than apoptosis-effector genes and have more regions of active chromatin: Connection to a stochastic paradigm for sequential gene expression programs. Cell Cycle. 14:2494–2500. 2015. View Article : Google Scholar : PubMed/NCBI
14	Lu H, Liang X, Issaenko OA and Hallstrom TC: Jab1/CSN5 mediates E2F dependent expression of mitotic and apoptotic but not DNA replication targets. Cell Cycle. 10:3317–3326. 2011. View Article : Google Scholar : PubMed/NCBI
15	Lu H and Hallstrom TC: The nuclear protein UHRF2 is a direct target of the transcription factor E2F1 in the induction of apoptosis. J Biol Chem. 288:23833–4333. 2013. View Article : Google Scholar : PubMed/NCBI
16	Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, Behm FG, Look AT, Lahti JM and Kidd VJ: Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med. 6:529–535. 2000. View Article : Google Scholar : PubMed/NCBI
17	Yavorski JM and Blanck G: TCGA: Increased oncoprotein coding region mutations correlate with a greater expression of apoptosis-effector genes and a positive outcome for stomach adenocarcinoma. Cell Cycle. 15:1–7. 2016. View Article : Google Scholar : PubMed/NCBI
18	Mauro JA, Butler SN, Ramsamooj M and Blanck G: Copy number loss or silencing of apoptosis-effector genes in cancer. Gene. 554:50–57. 2015. View Article : Google Scholar : PubMed/NCBI
19	Mauro JA, Yavorski JM and Blanck G: Stratifying melanoma and breast cancer TCGA datasets on the basis of the CNV of transcription factor binding sites common to proliferation- and apoptosis-effector genes. Gene. 614:37–48. 2017. View Article : Google Scholar : PubMed/NCBI
20	Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al: The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2:401–404. 2012. View Article : Google Scholar : PubMed/NCBI
21	Callahan BM, Patel JS, Fawcett TJ and Blanck G: Cytoskeleton and ECM tumor mutant peptides: Increased protease sensitivities and potential consequences for the HLA class I, mutant epitope reservoir. Int J Cancer. 142:988–998. 2017. View Article : Google Scholar : PubMed/NCBI
22	Yavorski JM and Blanck G: Smoking correlates with increased cytoskeletal protein-related coding region mutations in the lung and head and neck datasets of the cancer genome atlas. Physiol Rep. 4:pii: e13045. 2016. View Article : Google Scholar : PubMed/NCBI
23	Sikaria D, Tu YN, Fisler DA, Mauro JA and Blanck G: Identification of specific feed-forward apoptosis mechanisms and associated higher survival rates for low grade glioma and lung squamous cell carcinoma. J Cancer Res Clin Oncol. 144:459–468. 2018. View Article : Google Scholar : PubMed/NCBI
24	Lieberman J: Granzyme A activates another way to die. Immunol Rev. 235:93–104. 2010. View Article : Google Scholar : PubMed/NCBI